食管癌新辅助放化疗对手术及生存率的影响

Impact of neoadjuvant chemoradiotherapy on surgery and survival in patients with esophageal carcinoma

新辅助化疗常应用于实体肿瘤的手术前或围手术期,常联合应用放疗以提高生存率和治愈率,并对器官加以保护.手术仍是最有效的食管癌单一治疗手段.术前的(新辅助)化疗加放疗虽已经作为治疗食管癌的3种方法中的综合治疗模式存在近20余年,但他是否可作为食管癌的标准治疗模式仍存在争议.本文阐述了新辅助放化疗对食管癌手术及生存率的影响,提出了新辅助放化疗在食管癌治疗中的不足和发展方向.

Neoadjuvant chemotherapy is often used to treat solid tumors before surgery or during the perioperative period.It is often combined with radiotherapy to improve survival and cure rate and to protect normal organs.Surgery is still the most effective therapy for esophageal cancer.Preoperative（neoadjuvant） chemotherapy and radiotherapy as a treatment modality has been in existence for nearly 20 years.However,it remains controversial over whether neoadjuvant chemoradiotherapy can be used as the standard treatment for esophageal cancer.This paper sums up the impact of neoadjuvant chemotherapy on surgery and survival in patients with esophageal cancer.Moreover,we discuss the limitations and future directions of neoadjuvant chemotherapy for esophageal carcinoma.